Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Adam's Take

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By Adam Feuerstein

Adam's Take

This troubled biotech needed cash, so it turned to a predatory lender: its own CEO

By Adam Feuerstein

Adam's Take

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

By Adam Feuerstein

Adam's Take

Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future

By Adam Feuerstein

Adam's Take

With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug

By Adam Feuerstein

Adam's Take

The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies

By Adam Feuerstein

Adam's Take

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

By Adam Feuerstein

Vascepa pill handout
Adam's Take

Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: ResTORbio, Trovagene, Atossa Genetics

By Adam Feuerstein

Biotech

Biogen-Eisai partnership may be hitting a rough patch following Alzheimer’s drug blowup

By Adam Feuerstein

Adam's Take

Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bio-Path Holdings, CytoDyn

By Adam Feuerstein

Celgene breakup mix tape
Adam's Take

Suddenly, the Bristol-Celgene deal is looking shaky. What might be next for Celgene?

By Adam Feuerstein

Afrezza
Adam's Take

Wait … what? MannKind posts best-ever quarter of inhaled insulin product sales

By Adam Feuerstein

Adam's Take

Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Fennec Pharma, Actinium Pharma

By Adam Feuerstein

Fatty Liver
Adam's Take

What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical

By Adam Feuerstein

Hepatitis Drugs
Adam's Take

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Rexahn, Omeros, and Cel-Sci

By Adam Feuerstein

Close-up eye
Biotech

Aurinia’s flop in dry-eye trial brings an unexpected victory — and a shot at challenging Allergan

By Adam Feuerstein

Adam's Take

Lipocine fatty liver drug study results don’t hold up to scrutiny

By Adam Feuerstein

JPM 2019 - Painted Ladies
Adam's Take

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher

By Adam Feuerstein

JPM 2019 - Painted Ladies
Adam's Take

It’s day one at JPM19. Here’s what we heard and learned

By Adam Feuerstein

Westin St. Francis hotel
Adam's Take

On the cusp of the ‘JPM,’ here’s a cheat sheet for what to watch in biotech in 2019

By Adam Feuerstein

Good/Bad CEO 2017
Adam's Take

Leiden victorious in best biopharma CEO tally; Alles tops worst list

By Adam Feuerstein

Worst Biotech CEOs 2017
Adam's Take

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

By Adam Feuerstein

Best Biotech CEOs 2017
Adam's Take

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Why Gilead’s new CEO is a solid choice to help the biotech grow again

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy